NDAORALSUSPENSION
Approved
Dec 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
INDERAL (propranolol hydrochloride) by Thayer Medical is clinical pharmacology general propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. First approved in 1986.
Drug data last refreshed 8h ago · AI intelligence enriched 11h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Inderal (propranolol hydrochloride) is a nonselective beta-adrenergic receptor antagonist used to treat hypertension, angina pectoris, cardiac arrhythmias, and migraine prophylaxis. It works by blocking beta-adrenergic receptor sites, reducing heart rate, contractility, and blood pressure while decreasing myocardial oxygen demand. The drug also possesses membrane-stabilizing properties at higher doses similar to quinidine.
LOE Approaching
As a legacy product approaching loss of exclusivity, the brand team is likely focused on cost management and maximizing existing market share rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY General Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor-stimulating agents for available receptor sites. When access to beta-receptor sites is…
Worked on INDERAL at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.